"The increasing reliance on anxiety medication signals a societal shift, prompting urgent discussions about underlying causes, treatment efficacy, and the risks of oversimplification in mental healthcare."
The past few years have witnessed a significant rise in the prescription and use of anxiety medications across the United States. This trend, accelerated by the unique pressures of the COVID-19 pandemic and amplified by evolving societal factors, has brought to the forefront critical conversations about mental health, the role of pharmaceuticals, and the complex interplay between individual well-being and broader social influences. While these medications offer much-needed relief for millions, their escalating use has also sparked debate, with some advocating for alternative approaches and others questioning the long-term implications.
A Growing Dependence: Statistics Reveal a Significant Uptick in Anxiety Medication Use
Recent data from the Centers for Disease Control and Prevention (CDC) paints a clear picture of a nation grappling with increased anxiety. The proportion of American adults who have taken medication for anxiety rose from 11.7% in 2019 to 14.3% in 2024, translating to an additional 8 million individuals now relying on such treatments, bringing the total to approximately 38 million. This surge is particularly pronounced among young adults, those with higher education levels, and individuals identifying as LGBTQ+, suggesting a complex web of contributing factors. The pandemic acted as a significant catalyst, exacerbating pre-existing anxieties and introducing new stressors that pushed many to seek professional help, often through the increasingly accessible avenue of telemedicine.
For individuals like Sadia Zapp, a 40-year-old communications director from New York, the journey to medication was a direct response to overwhelming post-treatment anxiety following a year of intensive chemotherapy, surgery, and radiation for breast cancer. The lingering fear that "every little discomfort, like a knee ache, made me think: this is the end of the road for me" propelled her to seek relief. Zapp found that Lexapro, a selective serotonin reuptake inhibitor (SSRI) that boosts serotonin production, has been "excellent" and instrumental in managing her persistent anxiety. Her experience, while personal, mirrors that of millions who have found solace and stability through pharmacotherapy.
The SSRI Debate: Efficacy Versus Criticism
The widespread adoption of SSRIs, including widely prescribed medications like Prozac, Zoloft, and Lexapro, has become a focal point of discussion. Physicians and researchers largely support these drugs as first-line treatments for various anxiety disorders, such as generalized anxiety disorder and panic disorder, emphasizing their proven safety for long-term use. However, a vocal contingent, associated with the "Make America Healthy Again" (MAHA) movement, has raised concerns, characterizing these medications as potentially harmful and even addictive.
Robert F. Kennedy Jr., Secretary of the Department of Health and Human Services (HHS), has been a prominent critic. During his confirmation hearing, he controversially stated that some individuals, including family members, found it more difficult to discontinue SSRIs than heroin. More recently, he has suggested his agency is investigating a potential link between SSRIs and other psychiatric medications and instances of violent behavior, including school shootings. Similarly, Marty Makary, a commissioner on the Food and Drug Administration (FDA), has voiced concerns about the potential for ISRS use during pregnancy to lead to adverse birth outcomes.
These criticisms, however, are met with strong counterarguments from medical professionals. Patrick Kelly, president of the Southern California Psychiatric Society, asserts that "statements about SSRIs simply were not based on any type of evidence or fact," referring to Kennedy’s claims. He points to research indicating that SSRIs are not addictive, a sentiment echoed by numerous studies. Common side effects of SSRIs, such as stomach upset, difficulty concentrating, and fatigue, are often manageable for many, and some individuals may experience a reduced libido or other sexual side effects. Yet, for a significant portion of patients, the benefits of treating chronic anxiety far outweigh these potential drawbacks. A recent study published in the Cochrane Library demonstrated that over half of individuals with generalized anxiety disorder taking an SSRI experienced at least a 50% reduction in their symptoms, with only about 1 in 12 discontinuing due to side effects.
MAHA’s Perspective: Diet, Exercise, and Lifestyle as Pillars of Mental Wellness
The MAHA movement attributes the rise in anxiety and other mental health challenges, in part, to poor dietary choices and sedentary lifestyles. Their proposed solutions emphasize a return to foundational health principles, advocating for reduced consumption of ultra-processed foods – which recent studies have linked to depression and anxiety – and decreased screen time in favor of regular physical activity. Psychiatrists generally concur that a healthy diet and exercise serve as valuable complementary therapies for anxiety and depression. Emily Wood, a psychiatrist practicing in Los Angeles, suggests that individuals who can manage their anxiety without medication should also explore talk therapy, noting that anxiety disorders respond well to cognitive-behavioral therapy.
However, the narrative that lifestyle alone can fully address anxiety is challenged by the evidence supporting medication. While acknowledging the importance of diet and exercise, experts like Wood highlight that the risks associated with taking SSRIs during pregnancy are generally low for both mother and child, and that untreated maternal depression carries far greater risks. The government officials’ recent pronouncements on SSRI use in pregnancy, she argues, "could be causing real harm to these women."
Beyond SSRIs: Other Medications and Their Roles
The landscape of anxiety treatment extends beyond SSRIs. Benzodiazepines, such as Xanax, are often prescribed as a second-line treatment for acute anxiety. While effective in the short term, these controlled substances carry a risk of dependence and can increase the risk of opioid overdose when co-prescribed. Kennedy has also voiced concerns about the overuse of benzodiazepines. Wood cautions that these medications, while useful for acute anxiety, are not suitable for long-term daily use due to their potential for generating dependence over time, requiring gradual dose reduction.
A growing number of individuals are also using beta-blockers, like propranolol, off-label for anxiety. These medications, while not FDA-approved for anxiety treatment, can help prevent rapid heart rate in stressful situations, such as public speaking. While potential side effects include dizziness and fatigue, beta-blockers do not cause addiction and can help shift the body from a "fight or flight" response to a more neutral state, according to Wood.
Societal Shifts Fueling the Rise in Medication Use
Multiple theories attempt to explain the escalating use of anxiety medications. Increased social media engagement, growing social isolation, and heightened economic uncertainty are frequently cited by experts. Furthermore, the ease of access to these medications has played a significant role. Many individuals obtain prescriptions from their primary care physicians, while others secure them through brief telemedicine appointments.
The destigmatization of mental health issues, partly driven by social media influencers openly discussing their struggles, has encouraged younger generations to seek help. A recent Pew Research Center study indicated that about a third of teens seek mental health information via social media. However, this increased accessibility, when combined with a tendency to self-diagnose based on online information, can be problematic. Online searches for medications like Xanax can yield sponsored ads promising same-day treatment, underscoring the need for caution and professional medical guidance.
Young adults, aged 18-34, are leading the surge in anxiety medication use, with their utilization increasing from 8.8% in 2019 to 14.6% in 2024, according to CDC data. The COVID-19 pandemic and its associated lockdowns significantly heightened stress levels, particularly among this demographic.
The data also consistently shows that women are more likely than men to take anxiety medication. Jason Schnittker, Chair of Sociology at the University of Pennsylvania, suggests this may be due to women being more likely to need such treatments and more inclined to report feelings of anxiety. He also notes that physicians may be more adept at identifying anxiety in female patients. Broader societal trends, such as rising income inequality, increased social isolation, and a growing distrust among individuals, may also contribute to a pervasive sense of unease.
For Zapp, the impact of Lexapro became evident after several months. She describes feeling a significant reduction in mental clutter, allowing for improved concentration. While she also engaged in therapy, her chronic anxiety is now stabilized primarily through medication, enabling her to "definitely get back into my daily routine in a productive way and not just be riddled with anxiety all day long." Her experience underscores the potential of medication to be a crucial component in regaining a sense of normalcy and productivity for those struggling with significant anxiety.